What are the tumor sizes of alveolar soft part sarcoma?
Best insight from top research papers
The tumor sizes of alveolar soft part sarcoma (ASPS) vary across different studies. In a retrospective analysis conducted at the First Affiliated Hospital of Zhengzhou University, China, the mean tumor maximum diameter associated with a high lung metastasis rate was ≥ 5 cm . Another study reported a median tumor diameter of 55 mm, ranging from 10 to 130 mm, with the most common location being the thigh . Additionally, a comprehensive review of ASPS cases between 1975 and 2008 found a median tumor diameter of 9 cm, ranging from 2 to 15 cm, with the tumor being deeply located in most cases . These findings highlight the variability in tumor sizes observed in ASPS cases, emphasizing the importance of individualized treatment approaches based on tumor characteristics.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
84 Citations | The median tumor size of alveolar soft part sarcoma was 9 cm, ranging from 2 to 15 cm, as reported in the study. |
6 Citations | The tumor sizes of alveolar soft part sarcoma in the thyroid gland were 5.7 cm and 7.6 cm, as reported in the case study. |
27 Citations | Tumor sizes of alveolar soft part sarcoma ranged from 10 to 130 mm, with 47% exceeding 50 mm and 53% being less than or equal to 50 mm. |
| Tumor sizes of alveolar soft part sarcoma varied, with a tumor maximum diameter ≥ 5 cm associated with a high lung metastasis rate, as per the study. | |
| The average tumor size of alveolar soft part sarcoma (ASPS) was 7.2 cm, ranging from 2 to 14 cm, as reported in the study. |
Related Questions
What is the mean age for alveolar soft part sarcoma?5 answersThe mean age for alveolar soft part sarcoma (ASPS) varies across different studies. One study reported a median age at diagnosis of 24 years, with a range from 1.4 to 78 years, where women, especially those under 30 years old, were predominant. Another study mentioned that ASPS is commonly seen between the ages of 15 and 35 years, with a slight predilection in young women, and presented a case of a 36-year-old female with ASPS. Additionally, a study discussing primary bone involvement in ASPS patients reported ages ranging from 13 to 56 years, with five female and three male patients included in the analysis. Therefore, the mean age for ASPS can be estimated to be around the late teens to early thirties, with a slight female predominance.
How does the prognosis of musculoskeletal sarcoma cancers vary based on the location and size of the tumor?5 answersThe prognosis of musculoskeletal sarcoma cancers is influenced by various factors such as tumor location and size. Soft-tissue sarcomas, including extraskeletal myxoid chondrosarcoma (EMC), are rare and heterogeneous, with EMC showing high local recurrence and metastasis rates. Skeletal metastasis, common in sarcomas, affects patient survival and quality of life, with resection of the primary tumor significantly improving survival rates. In a study on sarcoma patients, surgical intervention was associated with better survival outcomes, with patients undergoing wide resections having improved prognosis. Additionally, the size of the tumor plays a crucial role, as larger tumors are associated with poorer prognoses, with a cutoff value of 11 cm identified as a significant factor for increased mortality in EMC patients.
What is the mean dogs weight with spleen hemangiosarcoma?5 answersThe mean weight of dogs diagnosed with splenic hemangiosarcoma varies across different studies. One study found that the mean weight of dogs undergoing splenectomy for splenic masses was 27.8 kg, with no significant difference in malignancy rates between small and large dogs. Another study focused on small breed (<20 kg) and large breed dogs with splenic hemangiosarcoma, reporting that the median survival time was 116 days for small breed dogs and 97 days for large breed dogs. Additionally, a clinical case highlighted a male mixed breed dog weighing 8 kg diagnosed with hemangiosarcoma of the spleen and liver. These findings collectively suggest that dogs diagnosed with splenic hemangiosarcoma can vary in weight, with no specific mean weight consistently reported across the studies.
What are the different forms of immunotherapy used for alveolar rhabdomyosarcoma?5 answersDifferent forms of immunotherapy for alveolar rhabdomyosarcoma include immune checkpoint inhibitors, vaccines, and adoptive cell therapy. Specifically, in the case of PAX3-FOXO1-expressing alveolar rhabdomyosarcoma, pharmacological ataxia telangiectasia and Rad3 related protein (ATR) inhibitors have shown sensitivity, leading to replication stress exacerbation and reduced DNA repair pathway activity. Moreover, chimeric antigen receptor (CAR)-modified T cells targeting platelet-derived growth factor receptor α (PDGFRA) have demonstrated promising results in PDGFRA-positive rhabdomyosarcoma, showing efficient cytotoxic activity and tumor regression in preclinical models. Additionally, oncolytic virotherapy in combination with a Janus kinase (JAK) inhibitor has shown benefits in reducing clinical signs and improving quality of life in mice with alveolar rhabdomyosarcoma. These diverse immunotherapeutic approaches highlight the potential for improved outcomes in patients with this challenging cancer.
Which kind of optimal treatment is there for patients with alveolar rhabdomyosarcoma?4 answersOptimal treatment for patients with alveolar rhabdomyosarcoma (ARMS) involves a multidisciplinary approach, including surgery, radiotherapy, and chemotherapy. In the course of ARMS, changes may be present in signaling pathways, including the RAS-PI3K pathway, Wnt/b-catenin pathway, receptor tyrosine kinase pathways, and myogenesis regulation. However, despite intensive treatment, the 5-year survival index for ARMS is not greater than 50%. A study has shown that ARMS cells expressing the PAX3-FOXO1 fusion oncogene are sensitive to pharmacological ataxia telangiectasia and Rad3 related protein (ATR) inhibition. ATR inhibitor treatment increases sensitivity of ARMS cells to PARP1 inhibition, and combined treatment with ATR and PARP1 inhibitors induces complete regression of primary patient-derived ARMS xenografts in vivo. These findings provide a rationale for upcoming biomarker-driven clinical trials of ATR inhibitors in patients suffering from ARMS.
What are the sites of first metastasis of different subtypes of soft tissue sarcoma?5 answersSoft tissue sarcomas can metastasize to various sites. The most common site of first metastasis for extremity soft tissue sarcomas is the lungs. Soft tissue metastases can also occur in other sites such as the skin, kidney, and colon, which are common sites of primary carcinomas. Different subtypes of soft tissue sarcoma may have different patterns of metastasis. For example, liposarcoma, undifferentiated pleomorphic sarcoma (UPS), and pleomorphic rhabdomyosarcoma are subtypes that are capable of metastasizing into the lungs. Soft tissue sarcomas can arise in various anatomical sites, with the most common being the extremities, trunk, retroperitoneum, and head and neck. Metastasis of visceral malignancies to soft tissue is not very common, but when it occurs, the most common primary tumors are lung and breast carcinoma, followed by gastrointestinal tract and female genital tract malignancies.